AntiCoagulants and COGnition (ACCOG Trial): a Single-blind Randomized Controlled Trial Comparing the Neurocognitive Effects of Rivaroxaban Versus Vitamin K Antagonist
Latest Information Update: 07 Jul 2023
Price :
$35 *
At a glance
- Drugs Rivaroxaban (Primary) ; Warfarin
- Indications Thrombosis
- Focus Therapeutic Use
- Acronyms ACCOG
- 06 Jul 2023 This trial has been discontinued (End Date: 29 Jun 2023), according to European Clinical Trials Database record.
- 25 Jul 2022 Planned End Date changed from 1 Mar 2021 to 1 Feb 2023.
- 25 Jul 2022 Planned primary completion date changed from 1 Mar 2021 to 1 Feb 2023.